These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17252717)

  • 21. [Biopharmaceutical industry's commitment to innovation and to the future of health care].
    Marini G
    Recenti Prog Med; 2006 Nov; 97(11):626-33. PubMed ID: 17252719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease.
    Doody RS
    Alzheimers Dement; 2009 Mar; 5(2):133-6. PubMed ID: 19328443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The Medical Product Agency's work and economics--a comment].
    Ahlqvist Rastad J; Salmonson T
    Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
    [No Abstract]   [Full Text] [Related]  

  • 24. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Physicians and drug industry--open cooperation is the way forward].
    Ibsen TB
    Ugeskr Laeger; 2004 Apr; 166(17):1585. PubMed ID: 15146699
    [No Abstract]   [Full Text] [Related]  

  • 26. [Medical development: conflict of interest?].
    Chabot JM
    Rev Prat; 2001 May; 51(10):1115-6. PubMed ID: 11468911
    [No Abstract]   [Full Text] [Related]  

  • 27. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 28. A place in the sun.
    Abbott A
    Nature; 2007 Mar; 446(7132):124-5. PubMed ID: 17344823
    [No Abstract]   [Full Text] [Related]  

  • 29. Commentary: Epidemiology and the pharmaceutical industry: an inside perspective.
    Haas J
    Int J Epidemiol; 2008 Feb; 37(1):53-5; discussion 65-8. PubMed ID: 18184672
    [No Abstract]   [Full Text] [Related]  

  • 30. [The function of the physician in the pharmaceutical industry].
    Vallvé C
    Med Clin (Barc); 1983 Nov; 81(16):717-9. PubMed ID: 6656427
    [No Abstract]   [Full Text] [Related]  

  • 31. [The drug industry and research: status in Germany].
    Geursen R
    Zentralbl Chir; 1996; 121(7):603-5. PubMed ID: 8967203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The influence of the pharmaceutical industry on treatment guidelines].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2429-31. PubMed ID: 18064860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The market and medical innovation: human passions and medical advancement.
    Cherry MJ
    J Med Philos; 2005 Dec; 30(6):555-69. PubMed ID: 16396784
    [No Abstract]   [Full Text] [Related]  

  • 34. Follow-on drugs and indications: the importance of incremental innovation to medical practice.
    Cohen J; Kaitin K
    Am J Ther; 2008; 15(1):89-91. PubMed ID: 18223359
    [No Abstract]   [Full Text] [Related]  

  • 35. [Status of research and development for control of tropical diseases: hypocrisy, indifference or lack of coordination].
    Millet P
    Med Trop (Mars); 2006 Dec; 66(6):542-8. PubMed ID: 17286017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the effect of pharmaceutical firm drug announcements on stock option pricing.
    Younis MM; Younies H; Kisa A; Hartmann M; Hussain AA; Al-Amro A
    J Health Care Finance; 2009; 35(3):35-43. PubMed ID: 19891206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [France, an attractive country for international clinical research: 2008 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S;
    Therapie; 2008; 63(5):345-57. PubMed ID: 19154705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 39. [Drug marketing: methods, effect and regulation].
    Søndergaard J; Koefoed MM; Andersen M
    Ugeskr Laeger; 2009 Mar; 171(10):778-80. PubMed ID: 19265598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.